In short
Gut microbiome testing analyzes DNA from a stool sample — typically via 16S rRNA sequencing or shotgun metagenomic sequencing — to characterize the bacterial species and their relative abundance living in the gut.
16S rRNA sequencing targets a specific bacterial gene to identify which genera or species are present and in what relative proportion; shotgun metagenomic sequencing reads much more of the DNA present, allowing finer species- and even strain-level resolution and some functional gene predictions, at higher cost. Both methods characterize a single stool sample, which reflects a mix of what's happening throughout the colon, not necessarily the small intestine or a comprehensive snapshot of gut function.
The research base connecting the gut microbiome to health outcomes is genuinely substantial and growing — associations have been found between microbiome composition and conditions including inflammatory bowel disease, obesity, and immune function, and dysbiosis (an imbalanced microbiome) was added as a proposed twelfth hallmark of aging in the 2023 hallmarks update. However, this research is largely correlational and population-level; the field has not converged on a validated definition of a single “healthy” or “optimal” microbiome profile that a test can score an individual against.
This is the central gap in commercial gut microbiome test interpretation: a report can accurately tell you what bacteria were present in your sample, but the personalized dietary or supplement recommendations many companies generate from that data — such as specific probiotic strain suggestions to correct an apparent imbalance — generally outrun what a single stool snapshot can reliably support, since microbiome composition is also highly variable day to day and influenced heavily by recent diet.